Regenicin (RGIN) Action Cours

Regenicin Inc develops regenerative cell therapies, focusing on tissue-engineered skin substitutes for burn treatment, chronic wounds, and plastic surgery. Its main product NovaDerm is a multi-layered skin substitute made from autologous skin cells, containing both epidermal and dermal components. The company also develops TempaDerm, which uses cryo-preserved cell banks to provide non-allogenic skin substitutes for smaller wounds like ulcers. Regenicin targets medical professionals and hospitals seeking advanced wound care solutions. NovaDerm is designed for grafting to restore healthy skin quality, while TempaDerm supports continuous supply for chronic wound treatments. The company's products are used by healthcare providers for burn and chronic wound care, with TempaDerm specifically addressing smaller wound areas. Regenicin's focus on autologous and non-allogenic solutions differentiates its offerings in the regenerative medicine market. The company's revenue streams come from the commercialization of NovaDerm and TempaDerm, targeting healthcare institutions and clinics specializing in wound care. Medical professionals and hospitals purchase these skin substitutes to treat patients with burns, chronic wounds, and plastic surgery needs, leveraging Regenicin's tissue-engineered solutions for improved patient outcomes.